PROTAC ERα Degrader-2 is primarily utilized in the field of targeted protein degradation, specifically for the estrogen receptor alpha (ERα). It is designed to address diseases driven by ERα, such as certain types of breast cancer. By employing the PROTAC (Proteolysis Targeting Chimera) technology, this compound facilitates the degradation of ERα, thereby inhibiting its function and reducing tumor growth. Its application is particularly significant in cases where traditional therapies, like hormone-based treatments, have shown resistance. This approach offers a novel strategy for combating ERα-positive cancers, potentially improving outcomes for patients with limited treatment options.